Broad Institute
MAY 30, 2024
Introduction to Pharmacogenetics By Rose Circeo May 30, 2024 Breadcrumb Home Introduction to Pharmacogenetics The Primer on Medical and Population Genetics is a series of weekly lectures on genetics topics related to human populations and disease.
The Open Targets Blog
MAY 9, 2024
In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Open Targets Blog
MARCH 20, 2024
We have implemented this analysis for eight sources of target-disease association evidence where there is enough information available to make an assessment. The assessment is tailored to each dataset; this is detailed in our target-disease evidence documentation. million evidence. is included as independent evidence.
The Open Targets Blog
NOVEMBER 30, 2023
The new page can be accessed from the target-disease associations page when searching for targets associated with a disease, and clicking on the target prioritisation factors tab. Target prioritisation view for Crohn's Disease. Clicking on one of the cells will bring up the data informing the assessment.
Drug Discovery World
OCTOBER 25, 2023
We can use NGS to better understand so-called “pharmacogenetics” so that we can predict how an individual may respond to a given treatment. RA: Are there any disease areas NGS technologies are having a particular impact in? However, NGS will have impact in any genetic-based diseases. DG : For sure!
Drug Discovery World
OCTOBER 5, 2022
The company envisions that its bioprinting technologies will help replicate complex disease models with subjects’ own cell lines to be cultured and tested for individual treatment which it states are not currently possible with conventional bioprinting and organ-on-a-chip technologies. .
ASPET
AUGUST 4, 2023
These findings have important clinical implications as PMAT could represent a novel molecular marker to help inform disease prognosis and predict response to 131 I-mIBG therapy. PMAT is expressed intracellularly in neuroblastoma cells, transports mIBG and thus could impact tumor retention and response to 131 I-mIBG therapy.
Expert insights. Personalized for you.
52 
Let's personalize your content